Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

BACKGROUND: The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors capable of predicting a pCR, such as the proliferation marker Ki67, may therefore help improve our understanding of the drug response...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasching, Peter A, Heusinger, Katharina, Haeberle, Lothar, Niklos, Melitta, Hein, Alexander, Bayer, Christian M, Rauh, Claudia, Schulz-Wendtland, Ruediger, Bani, Mayada R, Schrauder, Michael, Kahmann, Laura, Lux, Michael P, Strehl, Johanna D, Hartmann, Arndt, Dimmler, Arno, Beckmann, Matthias W, Wachter, David L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262864/
https://www.ncbi.nlm.nih.gov/pubmed/22081974
http://dx.doi.org/10.1186/1471-2407-11-486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262864/
https://www.ncbi.nlm.nih.gov/pubmed/22081974
http://dx.doi.org/10.1186/1471-2407-11-486

Ejemplares similares